Yahoo India Web Search

Sign In

Search results

  1. alexion.comAlexion

    Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders.

    • Our Commitment

      Giving at Alexion. We support important community...

    • Our Company

      At Alexion, our passion drives us to continuously innovate...

    • News & Media

      Alexion, AstraZeneca Rare Disease is focused on serving...

    • Contact Us

      To report an adverse event experience for any Alexion...

  2. www.astrazeneca-us.com › media › press-releasesAlexion, AstraZeneca Rare Disease to Acquire LogicBio ...

    Oct 3, 2022 · Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.

  3. www.astrazeneca.com › media-centre › press-releasesAlexion, AstraZeneca Rare Disease, enters agreement with ...

    Jul 28, 2023 · Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer).

  4. alexion.com › our-research › our-scienceOur Science - Alexion

    Leading Science in Rare Diseases, Every Day. With more than three decades of research and nearly 20 years of real-world evidence, we’ve proven what is possible in a variety of rare diseases and devastating conditions across neurology, hematology, nephrology, and metabolics.

  5. www.prnewswire.com › news-releases › alexion-astraAlexion, AstraZeneca Rare Disease to Acquire LogicBio ...

    Oct 3, 2022 · LEXINGTON, Mass., Oct. 3, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering clinical-stage genomic medicine company, today announced that it has entered into a...

  6. www.reuters.com › markets › dealsAstraZeneca's rare disease arm in $1 billion deal for Pfizer ...

    Jul 28, 2023 · The deal will bring a number of novel adeno-associated virus (AAV) capsids to Alexion and help build on Alexion and AstraZeneca's capabilities in genomic medicine.

  7. People also ask

  8. media.alexion.com › node › 24411Alexion, AstraZeneca Rare Disease, enters agreement with ...

    Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer).